Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03627754 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT03627754 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 24 participants.
The verdict
NCT03627754, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, parallel group, single dose study to investigate the effect of moderate or severe hepatic impairment on the PK of glasdegib, compared to subjects with normal hepatic function.
Interventions
- DRUG Glasdegib 100 mg single oral dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-11-05 |
| Est. Completion | 2019-04-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03627754
The ClinicalTrials.gov registry entry for NCT03627754 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glasdegib 100 mg single oral dose is the first listed.
NCT03627754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03627754 about?
NCT03627754 is a clinical study titled "A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib". This is a Phase 1, open-label, parallel group, single dose study to investigate the effect of moderate or severe hepatic impairment on the PK of glasdegib, compared to subjects with normal hepatic function.
What is the current status of trial NCT03627754?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2018-11-05. Estimated completion is 2019-04-11.
What interventions are being tested in trial NCT03627754?
The interventions under investigation include: Glasdegib 100 mg single oral dose (DRUG).
Who is sponsoring clinical trial NCT03627754?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.